Switch theme
Sign up to access all valuation multiples
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
2017
8.1K+
LTM Revenue $2.9B
LTM EBITDA $642M
$4.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Amneal Pharmaceuticals has a last 12-month revenue (LTM) of $2.9B and a last 12-month EBITDA of $642M.
In the most recent fiscal year, Amneal Pharmaceuticals achieved revenue of $2.8B and an EBITDA of $440M.
Amneal Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Amneal Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | XXX | $2.8B | XXX | XXX | XXX |
| Gross Profit | $1.2B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 37% | XXX | XXX | XXX |
| EBITDA | $642M | XXX | $440M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $573M | XXX | $347M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $205M | XXX | -$117M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | -4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Amneal Pharmaceuticals's stock price is $7.
Amneal Pharmaceuticals has current market cap of $2.3B, and EV of $4.8B.
See Amneal Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.8B | $2.3B | XXX | XXX | XXX | XXX | $0.63 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Amneal Pharmaceuticals has market cap of $2.3B and EV of $4.8B.
Amneal Pharmaceuticals's trades at 1.7x EV/Revenue multiple, and 10.9x EV/EBITDA.
Equity research analysts estimate Amneal Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Amneal Pharmaceuticals has a P/E ratio of 11.2x.
See valuation multiples for Amneal Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV (current) | $4.8B | XXX | $4.8B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 7.5x | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBIT | 8.4x | XXX | 13.8x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.2x | XXX | -19.6x | XXX | XXX | XXX |
| EV/FCF | 15.8x | XXX | 21.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAmneal Pharmaceuticals's last 12 month revenue growth is 8%
Amneal Pharmaceuticals's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Amneal Pharmaceuticals's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Amneal Pharmaceuticals's rule of X is 41% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Amneal Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 29% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amneal Pharmaceuticals acquired XXX companies to date.
Last acquisition by Amneal Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Amneal Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Amneal Pharmaceuticals founded? | Amneal Pharmaceuticals was founded in 2017. |
| Where is Amneal Pharmaceuticals headquartered? | Amneal Pharmaceuticals is headquartered in United States of America. |
| How many employees does Amneal Pharmaceuticals have? | As of today, Amneal Pharmaceuticals has 8.1K+ employees. |
| Who is the CEO of Amneal Pharmaceuticals? | Amneal Pharmaceuticals's CEO is Mr. Chirag Patel. |
| Is Amneal Pharmaceuticals publicy listed? | Yes, Amneal Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Amneal Pharmaceuticals? | Amneal Pharmaceuticals trades under AMRX ticker. |
| When did Amneal Pharmaceuticals go public? | Amneal Pharmaceuticals went public in 2018. |
| Who are competitors of Amneal Pharmaceuticals? | Similar companies to Amneal Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Amneal Pharmaceuticals? | Amneal Pharmaceuticals's current market cap is $2.3B |
| What is the current revenue of Amneal Pharmaceuticals? | Amneal Pharmaceuticals's last 12 months revenue is $2.9B. |
| What is the current revenue growth of Amneal Pharmaceuticals? | Amneal Pharmaceuticals revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Amneal Pharmaceuticals? | Current revenue multiple of Amneal Pharmaceuticals is 1.7x. |
| Is Amneal Pharmaceuticals profitable? | Yes, Amneal Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Amneal Pharmaceuticals? | Amneal Pharmaceuticals's last 12 months EBITDA is $642M. |
| What is Amneal Pharmaceuticals's EBITDA margin? | Amneal Pharmaceuticals's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Amneal Pharmaceuticals? | Current EBITDA multiple of Amneal Pharmaceuticals is 7.5x. |
| What is the current FCF of Amneal Pharmaceuticals? | Amneal Pharmaceuticals's last 12 months FCF is $304M. |
| What is Amneal Pharmaceuticals's FCF margin? | Amneal Pharmaceuticals's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Amneal Pharmaceuticals? | Current FCF multiple of Amneal Pharmaceuticals is 15.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
